Patients with cancer are characterized by a dysregulation of the hemostatic system and
systemic hypercoagulability. Different components of the hemostatic system are involved in …

Cancer patients present with abnormalities of coagulation tests, reflecting a
hypercoagulable state, often asso-ciated with a high incidence of thrombotic complications …

Background: Immune checkpoint inhibitors (ICIs) have shown efficacy in patients with
metastatic urothelial cancer (mUC), however, only a small subset of patients could benefit …

In cancer patients, hypercoagulability is a common finding. It has been associated with an
increased risk of venous thromboembolism, but also to tumor proliferation and progression …

Background The procoagulant phenotype in cancer is linked to thrombosis, cancer
progression, and immune response. A novel treatment that reduces the risk of both …

Osteosarcoma (OS) stands as the most prevalent primary bone cancer in children and
adolescents, and its limited treatment options often result in unsatisfactory outcomes …

Simple Summary Breast cancer cells travel via the bloodstream to the bone before the
cancer is detectable in the breast. These disseminated cells are resistant to adjuvant …

Background: Current online prognostic prediction models for breast cancer, such as
Adjuvant! Online and PREDICT, are based on specific populations. They have been well …

Purpose To evaluate the relationship between circulating tumor cells (CTCs) and standard
coagulation tests in both a discovery and a validation cohort of patients with advanced …

Simple Summary Breast cancer is the most common malignant neoplasm and the leading
cause of cancer death in women worldwide. The heterogeneity of breast cancer is a …